<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05116176</url>
  </required_header>
  <id_info>
    <org_study_id>2021P000054</org_study_id>
    <nct_id>NCT05116176</nct_id>
  </id_info>
  <brief_title>TRAjectories and CLinical ExpeRiences of ICD Therapy Study</brief_title>
  <acronym>TRACER-ICD</acronym>
  <official_title>TRAjectories and CLinical ExpeRiences of ICD Therapy Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebrew SeniorLife</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Saint Luke's Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective cohort study of older patients receiving implantable&#xD;
      cardioverter-defibrillators. The purpose of the TRACER-ICD study is to conduct a prospective&#xD;
      cohort investigation with the goal of 500 patients age &gt;65 receiving new primary prevention&#xD;
      implantable cardioverter-defibrillators (ICDs). Patients will be followed quarterly for 18&#xD;
      months with interviews, electronic record review, and remote monitoring to characterize&#xD;
      clinical and functional trajectories following device implantation, with permission for&#xD;
      extended electronic follow-up for up to 10 years (Aim 1). This cohort will support validation&#xD;
      and refinement of an established model for predicting personalized outcome profiles for ICD&#xD;
      therapies and death (Aim 2). Lastly, we will combine electronic record review with&#xD;
      semi-structured interviews with patients and physicians to evaluate physician and patient&#xD;
      experiences with a prototype individualized shared decision-making (SDM) tool (Aim 3).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Objectives and Design&#xD;
&#xD;
      The specific aims, applicable methods, and main hypotheses of the TRACER-ICD study are as&#xD;
      follows:&#xD;
&#xD;
      Aim 1: To characterize the clinical course of patients aged &gt;65 after ICD implantation by&#xD;
      establishing a multicenter prospective cohort (N=500). Baseline (verbal and in-person) and&#xD;
      quarterly (phone, electronic health records [EHR], remote monitoring) data collected up to 18&#xD;
      months or death will include: a. geriatric assessments (e.g. frailty, cognition,1 functional&#xD;
      status; b. comorbidities; c. quality of life and symptom burden; d. health services use; e.&#xD;
      SDM history; and f. ICD-recorded physical activity (minutes/day).&#xD;
&#xD;
      Factors associated with death and poor quality of life will be identified. Group-based&#xD;
      trajectory modeling will identify patient clusters with distinct trajectories of functional&#xD;
      status and quality of life following ICD implantation.&#xD;
&#xD;
      H1: A model integrating frailty and clinical factors will predict (a) death, (b) poor quality&#xD;
      of life, and (c) unfavorable functional trajectories after ICD implantation.&#xD;
&#xD;
      Aim 2: To validate a personalized prediction model of treatment outcomes of ICDs. We will&#xD;
      apply our established semi-competing risks approach5 to the prospective cohort, enriched by&#xD;
      the baseline geriatric assessments, to predict individual patients' probabilities of the&#xD;
      following outcome profiles at 6, 12, and 18 months post-implant: a. death without prior&#xD;
      shock, b. death with prior shock, c. survival without prior shock, and d. survival with prior&#xD;
      shock. The independent contribution of frailty, cognitive dysfunction, baseline quality of&#xD;
      life, and functional status (e.g. total deficits in ADL and IADL) to model performance will&#xD;
      be evaluated.&#xD;
&#xD;
      H2: Addition of frailty, cognitive dysfunction, quality of life, and functional status to a&#xD;
      model with cardiovascular variables will significantly improve model performance as assessed&#xD;
      by area under the curve (AUC).&#xD;
&#xD;
      Aim 3: To identify optimal strategies for incorporating personalized outcome profiles into&#xD;
      SDM. The main cohort's baseline interview and EHR review will provide quantitative data on&#xD;
      past SDM tools used by physicians. We will develop a prototype individualized version of the&#xD;
      Colorado SDM tool that incorporates 18-month outcome profiles using our semi-competing risk&#xD;
      model. We will perform semi-structured interviews of cardiologists (N=20) as well as patients&#xD;
      (N=20) recruited from the main cohort regarding process mapping of SDM from clinic to implant&#xD;
      procedure, including timing, content, format preferences, and impressions of the prototype&#xD;
      individualized tool.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Trajectories after ICD implantation</measure>
    <time_frame>Patients will be followed quarterly for 18 months or to death.</time_frame>
    <description>Group-based trajectory modeling will identify patient clusters with distinct trajectories of functional status and quality of life following ICD implantation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Outcomes after ICD Implantation</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Death/Poor Quality of Life (combined endpoint)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Semi-competing risks model of deaths and/or ICD shocks</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Personalized outcome profiles for death +/- ICD shocks</description>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Implantable Defibrillator User</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantable cardioverter-defibrillators</intervention_name>
    <description>500 patients age &gt;65 receiving new primary prevention implantable cardioverter-defibrillators (ICDs).</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients scheduled for ICD implantation will be identified at participating sites by site&#xD;
        staff. Eligibility criteria will include the following, all of which must be met by all&#xD;
        participants for participation:&#xD;
&#xD;
          1. Patient receiving new primary prevention ICD (single, dual chamber, or subcutaneous&#xD;
             system)&#xD;
&#xD;
          2. Age &gt;65 years&#xD;
&#xD;
          3. English-speaking (N.B.: assessment instruments are only available/validated in&#xD;
             English)&#xD;
&#xD;
          4. Sufficient cognitive ability to provide consent (i.e. answer simple questions on study&#xD;
             participation, purpose and procedures)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patients scheduled for ICD implantation will be identified at participating sites by site&#xD;
        staff. Eligibility criteria will include the following, all of which must be met by all&#xD;
        participants for participation:&#xD;
&#xD;
          1. Patient receiving new primary prevention ICD (single, dual chamber, or subcutaneous&#xD;
             system)&#xD;
&#xD;
          2. Age &gt;65 years&#xD;
&#xD;
          3. English-speaking (assessment instruments are only available/validated in English)&#xD;
&#xD;
          4. Sufficient cognitive ability to provide consent (i.e. answer simple questions on study&#xD;
             participation, purpose and procedures)&#xD;
&#xD;
        Candidates meeting the following exclusion criteria at baseline will be excluded from study&#xD;
        participation:&#xD;
&#xD;
          1. Receipt of cardiac resynchronization therapy device&#xD;
&#xD;
          2. Participation in another investigational drug or intervention trial expected to&#xD;
             influence any of the outcomes of interest in this study&#xD;
&#xD;
          3. Current drug or alcohol use or dependence that, in the opinion of the Site Principle&#xD;
             Investigator, would interfere with adherence to study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel B Kramer, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel B. Kramer, MD, MPH</last_name>
    <phone>617-667-8800</phone>
    <email>dkramer@bidmc.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lindsay H. Duchesneau, MPA</last_name>
    <phone>617-632-7731</phone>
    <email>lduchesn@bidmc.harvard.edu</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 12, 2021</study_first_submitted>
  <study_first_submitted_qc>November 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Dan B. Kramer</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

